whole-genome characterization chemoresistant ovarian cancer
patients high-grade serous ovarian cancer hgsc experienced little improvement overall survival standard treatment advanced beyond platinum-based combination chemotherapy past years understand drivers clinical phenotypes better use whole-genome sequencing tumour germline dna samples patients primary refractory resistant sensitive matched acquired resistant disease show gene breakage commonly inactivates tumour suppressors rb1 nf1 rad51b pten hgsc contributes acquired chemotherapy resistance ccne1 amplification common primary resistant refractory disease observed several molecular events associated acquired resistance including multiple independent reversions germline brca1 brca2 mutations individual patients loss brca1 promoter methylation alteration molecular subtype recurrent promoter fusion associated overexpression drug efflux pump mdr1
